Licensing status

Publication and contact information



Tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a)

A study in mice suggests decreasing TNFRSF1A could improve the safety of tumor necrosis factor (TNF)-based cancer treatments. In mouse models for cancer, an anti-TNFRSF1A mAb decreased the frequency of lethal toxicity compared with control antibody but preserved the antitumor effect of TNF treatment. In transgenic mice expressing human TNFRSF1A, a pegylated anti-TNFRSF1A Fab fragment prevented acute TNF-mediated lethality but enabled full TNF-mediated tumor regression. Next steps include assessing heterogeneity of TNFRSF1A levels in human patients and confirming safety and efficiency of the antibody in other solid tumors, including in animal models for spontaneous tumor development.

SciBX 6(22); doi:10.1038/scibx.2013.543
Published online June 6, 2013

Patent status not applicable; models and tools available for licensing

Van Hauwermeiren, F. et al.
J. Clin. Invest.
; published online
May 15, 2013;
Contact: George Kollias, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece
Contact: Claude Libert, Flancers Institute for Biotechnology and Ghent University, Ghent, Belgium